Impact of the Current International Situation on Exports of Medical Supplies

April 13, 2026

The current international landscape (geopolitical conflicts, trade protectionism, supply chain restructuring, regulatory barriers, logistics and inflation) has created an overall impact on medical supplies exports: short-term increases in costs, order diversion, and mounting compliance pressure, while forcing market diversification and high-end upgrading in the medium to long term. This is systematically explained from three perspectives: core impact dimensions, market-specific effects, and strategic responses.

I. Core Impacts: Five Key Factors

1. Geopolitics and Trade Barriers (Most Direct Impact)

United States: Dual pressure from tariffs and supply chain security. Starting in April 2026, a 100% tariff will be imposed on patented drugs and high-end APIs (15% for allies). The U.S. has tightened FDA on-site inspections and restricted public procurement under the pretext of "national security". The Section 301 tariffs on China (with exemptions for some medical consumables extended to November 2026) remain in place, driving nearshoring/friendshoring (with production capacity taken over by Mexico and Eastern Europe), squeezing the export space for low-end consumables and high-end devices.
European Union: Technical barriers and procurement restrictions. The EU has strengthened CE certification and MDR/IVDR compliance, restricting Chinese enterprises from participating in large-scale public medical procurement. It promotes "European medical autonomy", reduces reliance on high-risk Asian devices, and shifts procurement to nearshore sources (Eastern Europe, North Africa).
Other Regions: Stricter localization and market access. India, Brazil, the Middle East and other regions have raised registration/certification thresholds, enforced local packaging/assembly or manufacturing requirements, and imposed anti-dumping duties, increasing export barriers and costs.

2. Supply Chain Restructuring: Deglobalization, Regionalization and Nearshoring

The U.S. and EU are promoting domestic/friendshoring production of critical medical supplies (APIs, sterile consumables, ventilators) to reduce single-source dependence. Multinational giants are accelerating the establishment of factories in Mexico, Poland and Vietnam, diverting export orders from China.

Prices of upstream raw materials (medical plastics, APIs, packaging) have risen by 15%–25% due to conflicts in the Middle East, oil price fluctuations and chemical supply volatility, squeezing export profit margins.

Key components (chips, sensors, precision parts) are subject to export controls, restricting exports of high-end equipment (patient monitors, imaging devices, IVD products) and prolonging delivery cycles.

3. Logistics and Shipping: Skyrocketing Costs and Uncontrollable Timeliness

Conflicts in the Red Sea/Hormuz Strait have forced shipping lines to reroute via the Cape of Good Hope, extending maritime transit time by 10–15 days, raising freight and war risk insurance by 300%–500%, and increasing comprehensive logistics costs by 15%–25%. Risks for temperature-controlled/cold-chain medical devices (vaccines, reagents) have risen sharply, along with high demurrage charges.

Port congestion, tight container space and stricter cross-border customs clearance have caused difficulties in delivering small and urgent orders, increasing risks of order losses and contract breaches.

4. Regulation and Compliance: Overall Higher Thresholds

Global regulatory tightening has reduced mutual recognition between FDA, CE and NMPA, extended registration cycles, intensified audits and on-site inspections, and raised compliance costs by 30%–50%. Requirements for traceability, GMP, sterilization, biocompatibility and data compliance have been upgraded.

Green/carbon barriers such as the EU CBAM, eco-labels and packaging recycling rules have added extra costs for export compliance and certification.

5. Demand and Exchange Rates: Diversification and Volatility

Developed Markets (US, EU, Japan): Demand is relatively rigid, but budgets are tightening and procurement favors local/nearshore suppliers. Low-end consumables face intense price competition.
Emerging Markets (Middle East, Latin America, Southeast Asia, Africa): Driven by expanding medical infrastructure, demand is growing rapidly and becoming the main pillar of export growth. However, these markets vary greatly in payment capacity, certification and localization requirements.

Fluctuations in exchange rates (USD, EUR, CNY) have compressed export profits and increased risks in pricing and settlement.

II. Market-Specific Impacts (Key Focus)

U.S. Market: Under the greatest short-term pressure. High tariffs on high-end drugs/devices, procurement restrictions and rising compliance costs. Low-end consumables (gloves, syringes, dressings) still enjoy rigid demand but with thinner profits and order diversion to Mexico. Positive side: some exempted categories and emergency/basic consumables remain stable.
EU Market: The highest compliance threshold. MDR/IVDR regulations have forced many SMEs to exit the market, and public procurement access is restricted. However, high-end imaging, IVD and rehabilitation devices still hold potential, requiring stronger CE certification and localized services.
Emerging Markets (Middle East, Latin America, ASEAN, Africa): Major growth window. Spillover from European and American supply chains amid geopolitical conflicts and insufficient local capacity have boosted demand for low-end consumables and basic diagnostic supplies. However, adaptation to local certification, payment, after-sales service and localized registration is required.
Belt and Road/RCEP Markets: Preferential tariffs and supply chain coordination serve as important alternatives to avoid EU and U.S. barriers, with export growth rates generally higher than those to Europe and the United States.

III. Export Structure and Enterprise Differentiation

Product-wise: Low-value consumables (gloves, masks, infusion sets) suffer the heaviest impact (price wars, tariffs, capacity relocation). Medium and high-end devices (monitors, ultrasound, IVD, rehabilitation) show stronger resilience and steadier growth thanks to certification and technical barriers. APIs and intermediates enjoy short-term rigid demand but face long-term competition from India/Southeast Asia and supply chain relocation risks.
Enterprise-wise: Leading manufacturers (with FDA/CE certifications, global production capacity and diversified channels) have strong risk resistance. SMEs (relying on single markets, low-end products and lacking certifications) face declining orders and survival pressures, accelerating industry consolidation.

IV. Core Strategic Responses (For Export Enterprises)

Market Diversification: Reduce over-reliance on single markets. Focus on ASEAN, the Middle East, Latin America, Africa and the Belt and Road regions to lower concentration risks in Europe and the United States.
Product Upgrading + Compliance Enhancement: Shift from consumables to medium and high-end devices, IVD, rehabilitation and digital healthcare. Obtain core certifications such as CE, FDA and ANVISA in advance, and improve quality and traceability systems.
Supply Chain Resilience: Nearshore and localized layout. Set up assembly/packaging bases in Mexico, Vietnam and Eastern Europe to avoid tariffs and geopolitical risks. Lock in core raw materials and establish dual-supplier systems.
Logistics and Risk Control Optimization: Adopt multi-route transportation (ocean, air, land), develop temperature-controlled/cold-chain solutions, use forward foreign exchange hedging, and purchase war risk/credit insurance to control costs and delivery risks.